Exelixis
EXEL
#1582
Rank
โ‚ฌ9.77 B
Marketcap
34,92ย โ‚ฌ
Share price
-2.86%
Change (1 day)
70.16%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of December 2024 : โ‚ฌ2.70 Billion

According to Exelixis's latest financial reports the company's total assets are โ‚ฌ2.70 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2024-12-31โ‚ฌ2.83 B6.42%
2023-12-31โ‚ฌ2.66 B-7.05%
2022-12-31โ‚ฌ2.86 B23.95%
2021-12-31โ‚ฌ2.31 B32.94%
2020-12-31โ‚ฌ1.73 B3.23%
2019-12-31โ‚ฌ1.68 B35.39%
2018-12-31โ‚ฌ1.24 B127.64%
2017-12-31โ‚ฌ0.54 B-3.57%
2016-12-31โ‚ฌ0.56 B86.34%
2015-12-31โ‚ฌ0.30 B14.35%
2014-12-31โ‚ฌ0.26 B-27.06%
2013-12-31โ‚ฌ0.36 B-33.15%
2012-12-31โ‚ฌ0.54 B80.02%
2011-12-31โ‚ฌ0.30 B11.64%
2010-12-31โ‚ฌ0.27 B13.16%
2009-12-31โ‚ฌ0.23 B-16.57%
2008-12-31โ‚ฌ0.28 B1.78%
2007-12-31โ‚ฌ0.28 B-5.81%
2006-12-31โ‚ฌ0.29 B6.7%
2005-12-31โ‚ฌ0.28 B30.77%
2004-12-31โ‚ฌ0.21 B-24.43%
2003-12-31โ‚ฌ0.28 B-12.4%
2002-12-31โ‚ฌ0.32 B-17.34%
2001-12-31โ‚ฌ0.39 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
โ‚ฌ68.51 B 2,431.50%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ126.88 B 4,588.15%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ107.52 B 3,872.81%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ85.02 B 3,041.54%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ84.32 B 3,015.63%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ165.37 B 6,010.00%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ195.94 B 7,139.43%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ38.99 M-98.56%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ92.95 M-96.57%๐Ÿ‡บ๐Ÿ‡ธ USA